Literature DB >> 2423702

Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.

S D Marlin, S L Highlander, T C Holland, M Levine, J C Glorioso.   

Abstract

Monoclonal antibody-resistant (mar) mutants altered in the antigenic structure of glycoprotein B (gB) of herpes simplex virus type 1, strain KOS-321, were selected by neutralization with each of six independently derived gB-specific monoclonal antibodies. Analysis of the reactivity patterns of these mar mutants with a panel of 16 virus-neutralizing monoclonal antibodies identified at least five nonoverlapping epitopes on this antigen, designated groups I through V. Multiple mar mutations were also introduced into the gB structural gene by recombination and sequential antibody selection to produce a set of mar mutants with double, triple, and quadruple epitope alterations. Group II (B2) and group III (B4) antibodies were used to select the corresponding mutants, mar B2.1 and mar B4.1, which in addition to carrying the mar phenotype were temperature sensitive (ts) for processing of the major partially glycosylated precursor of gB, pgB (Mr = 107,000), to mature gB (Mr = 126,000) and showed reduced levels of gB on the cell surface at high temperature (39 degrees C). These mutants were not, however, ts for production of infectious progeny. A recombinant virus, mar B2/4.1, carrying both of these alterations was ts for virus production and failed to produce and transport any detectable mature gB to the cell surface at 39 degrees C. Rather, pgB accumulated in the infected cell. Revertants of the ts phenotype, isolated from virus plaques at 39 degrees C, regained the B2 but not the B4 epitope and were phenotypically indistinguishable from the mar B4.1 parent. Finally, it was shown that group II (B5) and group III (B4) antibodies failed to immunoprecipitate pgB (39 degrees C) produced by ts gB mutants of herpes simplex virus type 1 which were not selected with monoclonal antibodies. Taken together, our findings indicate that (i) mar mutations can alter antigenic as well as other functional domains of gB, namely, the domain(s) involved in processing and infectivity, and (ii) group II and group III epitopes lie within an essential functional domain of gB which is a target for ts gB mutations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423702      PMCID: PMC253049     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Membrane proteins specified by herpes simplex viruses. I. Identification of four glycoprotein precursors and their products in type 1-infected cells.

Authors:  P G Spear
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

2.  Serological analysis of herpes simplex virus types 1 and 2 with monoclonal antibodies.

Authors:  L Pereira; D V Dondero; D Gallo; V Devlin; J D Woodie
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

Review 3.  Antigenic characterization of viruses by monoclonal antibodies.

Authors:  J W Yewdell; W Gerhard
Journal:  Annu Rev Microbiol       Date:  1981       Impact factor: 15.500

4.  A virion-associated glycoprotein essential for infectivity of herpes simplex virus type 1.

Authors:  S P Little; J T Jofre; R J Courtney; P A Schaffer
Journal:  Virology       Date:  1981-11       Impact factor: 3.616

5.  Immune responses in mice against herpes simplex virus: mechanisms of protection against facial and ganglionic infections.

Authors:  H J Zweerink; D Martinez; R J Lynch; L W Stanton
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

6.  The involvement of herpes simplex virus type 1 glycoproteins in cell-mediated immunity.

Authors:  V C Carter; P A Schaffer; S S Tevethia
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

7.  Alterations in glycoprotein gB specified by mutants and their partial revertants in herpes simplex virus type 1 and relationship to other mutant phenotypes.

Authors:  M L Haffey; P G Spear
Journal:  J Virol       Date:  1980-07       Impact factor: 5.103

8.  Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection.

Authors:  J E Oakes; H Rosemond-Hornbeak
Journal:  Infect Immun       Date:  1978-08       Impact factor: 3.441

9.  Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.

Authors:  R D Dix; L Pereira; J R Baringer
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

10.  Lymphocyte reactivity contributes to protection conferred by specific antibody passively transferred to herpes simplex virus-infected mice.

Authors:  J E Oakes; W B Davis; J A Taylor; W A Weppner
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

View more
  26 in total

1.  Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

Authors:  D B Anderson; S Laquerre; K Ghosh; H P Ghosh; W F Goins; J B Cohen; J C Glorioso
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions.

Authors:  Florent C Bender; Minu Samanta; Ekaterina E Heldwein; Manuel Ponce de Leon; Elina Bilman; Huan Lou; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

3.  Capturing the herpes simplex virus core fusion complex (gB-gH/gL) in an acidic environment.

Authors:  Tina M Cairns; J Charles Whitbeck; Huan Lou; Ekaterina E Heldwein; Tirumala K Chowdary; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

4.  Serologic type conversion of a herpes simplex virus type 1 (HSV-1) to an HSV-2 epitope caused by a single amino acid substitution in glycoprotein C.

Authors:  K A Kimmel; K E Dolter; G M Toth; M Levine; J C Glorioso
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

5.  Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants.

Authors:  M I Muggeridge; V J Isola; R A Byrn; T J Tucker; A C Minson; J C Glorioso; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

6.  The carboxy-terminal 41 amino acids of herpes simplex virus type 1 glycoprotein B are not essential for production of infectious virus particles.

Authors:  V Huff; W Cai; J C Glorioso; M Levine
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Using Antibodies and Mutants To Localize the Presumptive gH/gL Binding Site on Herpes Simplex Virus gD.

Authors:  Doina Atanasiu; Wan Ting Saw; Eric Lazear; J Charles Whitbeck; Tina M Cairns; Huan Lou; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

8.  Linker-insertion nonsense and restriction-site deletion mutations of the gB glycoprotein gene of herpes simplex virus type 1.

Authors:  W Z Cai; S Person; S C Warner; J H Zhou; N A DeLuca
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

9.  Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration.

Authors:  S L Highlander; S L Sutherland; P J Gage; D C Johnson; M Levine; J C Glorioso
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

10.  Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread.

Authors:  S Laquerre; R Argnani; D B Anderson; S Zucchini; R Manservigi; J C Glorioso
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.